- Home
- LDWY vs NLSP Comparison
LDWY vs NLSP Comparison
Compare LDWY & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- NLSP
- Stock Information
- Founded
- LDWY 1990
- NLSP 2015
- Country
- LDWY United States
- NLSP Switzerland
- Employees
- LDWY N/A
- NLSP N/A
- Industry
- LDWY Advertising
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- NLSP Health Care
- Exchange
- LDWY Nasdaq
- NLSP Nasdaq
- Market Cap
- LDWY 9.2M
- NLSP 12.4M
- IPO Year
- LDWY 1991
- NLSP 2021
- Fundamental
- Price
- LDWY $4.79
- NLSP $2.10
- Analyst Decision
- LDWY
- NLSP
- Analyst Count
- LDWY 0
- NLSP 0
- Target Price
- LDWY N/A
- NLSP N/A
- AVG Volume (30 Days)
- LDWY 3.6K
- NLSP 269.6K
- Earning Date
- LDWY 08-18-2025
- NLSP 07-22-2025
- Dividend Yield
- LDWY N/A
- NLSP N/A
- EPS Growth
- LDWY N/A
- NLSP N/A
- EPS
- LDWY N/A
- NLSP N/A
- Revenue
- LDWY $42,183,000.00
- NLSP N/A
- Revenue This Year
- LDWY N/A
- NLSP N/A
- Revenue Next Year
- LDWY N/A
- NLSP N/A
- P/E Ratio
- LDWY N/A
- NLSP N/A
- Revenue Growth
- LDWY 425.12
- NLSP N/A
- 52 Week Low
- LDWY $3.02
- NLSP $1.30
- 52 Week High
- LDWY $5.53
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- LDWY 60.30
- NLSP 46.61
- Support Level
- LDWY $4.56
- NLSP $2.20
- Resistance Level
- LDWY $5.23
- NLSP $3.08
- Average True Range (ATR)
- LDWY 0.22
- NLSP 0.25
- MACD
- LDWY 0.00
- NLSP -0.06
- Stochastic Oscillator
- LDWY 89.52
- NLSP 8.40
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.